Lake Street Capital Begins Coverage on Organogenesis (NASDAQ:ORGO)

Lake Street Capital started coverage on shares of Organogenesis (NASDAQ:ORGO) in a report published on Friday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $5.00 price objective on the stock.

Separately, Cantor Fitzgerald reiterated an overweight rating and issued a $5.00 price target on shares of Organogenesis in a report on Friday, March 1st.

Organogenesis Stock Down 3.6 %

ORGO opened at $2.70 on Friday. The stock has a market cap of $357.94 million, a price-to-earnings ratio of 67.50 and a beta of 1.66. The company has a debt-to-equity ratio of 0.22, a quick ratio of 2.41 and a current ratio of 2.74. The firm’s fifty day moving average is $2.62 and its 200 day moving average is $3.11. Organogenesis has a fifty-two week low of $1.96 and a fifty-two week high of $4.70.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.01. The business had revenue of $109.98 million for the quarter, compared to the consensus estimate of $100.44 million. Organogenesis had a return on equity of 2.11% and a net margin of 1.34%. During the same period in the previous year, the business earned ($0.02) earnings per share. On average, sell-side analysts forecast that Organogenesis will post -0.05 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Jacobs Levy Equity Management Inc. increased its position in Organogenesis by 349.1% in the first quarter. Jacobs Levy Equity Management Inc. now owns 186,236 shares of the company’s stock worth $529,000 after purchasing an additional 144,771 shares during the last quarter. Caxton Associates LP bought a new stake in shares of Organogenesis in the 1st quarter worth about $88,000. Price T Rowe Associates Inc. MD raised its position in shares of Organogenesis by 11.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 50,951 shares of the company’s stock valued at $145,000 after buying an additional 5,359 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Organogenesis in the 1st quarter valued at about $1,846,000. Finally, Connors Investor Services Inc. grew its position in Organogenesis by 58.1% in the first quarter. Connors Investor Services Inc. now owns 68,000 shares of the company’s stock worth $193,000 after acquiring an additional 25,000 shares in the last quarter. 49.57% of the stock is currently owned by institutional investors.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.